发布求助
文献互助 智能选刊 最新文献

Advances in clinical chemistry最新文献

筛选
英文 中文
Extracellular vesicles in heart failure. 心力衰竭中的细胞外囊泡
Advances in clinical chemistry Pub Date : 2024-01-01 Epub Date: 2024-02-24 DOI: 10.1016/bs.acc.2024.02.001
Alexander E Berezin, Alexander A Berezin
{"title":"Extracellular vesicles in heart failure.","authors":"Alexander E Berezin, Alexander A Berezin","doi":"10.1016/bs.acc.2024.02.001","DOIUrl":"10.1016/bs.acc.2024.02.001","url":null,"abstract":"<p><p>Physiologically, extracellular vesicles (EVs) have been implicated as crucial mediators of immune response, cell homeostasis, angiogenesis, cell differentiation and growth, and tissue repair. In heart failure (HF) they may act as regulators of cardiac remodeling, microvascular inflammation, micro environmental changes, tissue fibrosis, atherosclerosis, neovascularization of plaques, endothelial dysfunction, thrombosis, and reciprocal heart-remote organ interaction. The chapter summaries the nomenclature, isolation, detection of EVs, their biologic role and function physiologically as well as in the pathogenesis of HF. Current challenges to the utilization of EVs as diagnostic and predictive biomarkers in HF are also discussed.</p>","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"119 ","pages":"1-32"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140186826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitochondria: A source of potential biomarkers for non-communicable diseases. 线粒体：非传染性疾病的潜在生物标志物来源。
Advances in clinical chemistry Pub Date : 2024-01-01 Epub Date: 2024-04-20 DOI: 10.1016/bs.acc.2024.04.007
Amulya Ichegiri, Kshitij Kodolikar, Vaibhavi Bagade, Mrunal Selukar, Tuli Dey
{"title":"Mitochondria: A source of potential biomarkers for non-communicable diseases.","authors":"Amulya Ichegiri, Kshitij Kodolikar, Vaibhavi Bagade, Mrunal Selukar, Tuli Dey","doi":"10.1016/bs.acc.2024.04.007","DOIUrl":"https://doi.org/10.1016/bs.acc.2024.04.007","url":null,"abstract":"<p><p>Mitochondria, as an endosymbiont of eukaryotic cells, controls multiple cellular activities, including respiration, reactive oxygen species production, fatty acid synthesis, and death. Though the majority of functional mitochondrial proteins are translated through a nucleus-controlled process, very few of them (∼10%) are translated within mitochondria through their own machinery. Germline and somatic mutations in mitochondrial and nuclear DNA significantly impact mitochondrial homeostasis and function. Such modifications disturbing mitochondrial biogenesis, metabolism, or mitophagy eventually resulted in cellular pathophysiology. In this chapter, we discussed the impact of mitochondria and its dysfunction on several non-communicable diseases like cancer, diabetes, neurodegenerative, and cardiovascular problems. Mitochondrial dysfunction and its outcome could be screened by currently available omics-based techniques, flow cytometry, and high-resolution imaging. Such characterization could be evaluated as potential biomarkers to assess the disease burden and prognosis.</p>","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"121 ","pages":"334-365"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141154187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cortisol in metabolic syndrome. 代谢综合征中的皮质醇
Advances in clinical chemistry Pub Date : 2024-01-01 Epub Date: 2024-06-24 DOI: 10.1016/bs.acc.2024.06.008
Eglė Mazgelytė, Dovilė Karčiauskaitė
{"title":"Cortisol in metabolic syndrome.","authors":"Eglė Mazgelytė, Dovilė Karčiauskaitė","doi":"10.1016/bs.acc.2024.06.008","DOIUrl":"https://doi.org/10.1016/bs.acc.2024.06.008","url":null,"abstract":"<p><p>Cortisol, a stress hormone, plays a crucial role in regulating metabolic, hemodynamic, inflammatory, and behavioral processes. Its secretion is governed by the hypothalamic-pituitary-adrenal axis. However, prolonged activation of this axis and increased cortisol bioavailability in tissues can result in detrimental metabolic effects. Chronic exposure to excessive cortisol is associated with insulin resistance and visceral obesity, both significant contributors to metabolic syndrome. This review delves into the regulation of the hypothalamic-pituitary-adrenal axis, the molecular mechanisms underlying cortisol synthesis and its actions, as well as the key factors influencing cortisol bioavailability. Furthermore, it provides a summary of available clinical research data on the involvement of cortisol in metabolic syndrome, alongside a discussion on the various biomatrices used for cortisol measurement in clinical settings.</p>","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"123 ","pages":"129-156"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142057796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fibrinogen: Structure, abnormalities and laboratory assays. 纤维蛋白原：结构、异常和实验室检测。
Advances in clinical chemistry Pub Date : 2024-01-01 Epub Date: 2024-04-30 DOI: 10.1016/bs.acc.2024.03.004
Berrak Güven, Murat Can
{"title":"Fibrinogen: Structure, abnormalities and laboratory assays.","authors":"Berrak Güven, Murat Can","doi":"10.1016/bs.acc.2024.03.004","DOIUrl":"https://doi.org/10.1016/bs.acc.2024.03.004","url":null,"abstract":"<p><p>Fibrinogen is the primary precursor protein for the fibrin clot, which is the final target of blood clotting. It is also an acute phase reactant that can vary under physiologic and inflammatory conditions. Disorders in fibrinogen concentration and/or function have been variably linked to the risk of bleeding and/or thrombosis. Fibrinogen assays are commonly used in the management of bleeding as well as the treatment of thrombosis. This chapter examines the structure of fibrinogen, its role in hemostasis as well as in bleeding abnormalities and measurement thereof with respect to clinical management.</p>","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"120 ","pages":"117-143"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140961436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood-brain barrier biomarkers. 血脑屏障生物标志物
Advances in clinical chemistry Pub Date : 2024-01-01 Epub Date: 2024-04-22 DOI: 10.1016/bs.acc.2024.04.004
Juan F Zapata-Acevedo, Alejandra Mantilla-Galindo, Karina Vargas-Sánchez, Rodrigo E González-Reyes
{"title":"Blood-brain barrier biomarkers.","authors":"Juan F Zapata-Acevedo, Alejandra Mantilla-Galindo, Karina Vargas-Sánchez, Rodrigo E González-Reyes","doi":"10.1016/bs.acc.2024.04.004","DOIUrl":"https://doi.org/10.1016/bs.acc.2024.04.004","url":null,"abstract":"<p><p>The blood-brain barrier (BBB) is a dynamic interface that regulates the exchange of molecules and cells between the brain parenchyma and the peripheral blood. The BBB is mainly composed of endothelial cells, astrocytes and pericytes. The integrity of this structure is essential for maintaining brain and spinal cord homeostasis and protection from injury or disease. However, in various neurological disorders, such as traumatic brain injury, Alzheimer's disease, and multiple sclerosis, the BBB can become compromised thus allowing passage of molecules and cells in and out of the central nervous system parenchyma. These agents, however, can serve as biomarkers of BBB permeability and neuronal damage, and provide valuable information for diagnosis, prognosis and treatment. Herein, we provide an overview of the BBB and changes due to aging, and summarize current knowledge on biomarkers of BBB disruption and neurodegeneration, including permeability, cellular, molecular and imaging biomarkers. We also discuss the challenges and opportunities for developing a biomarker toolkit that can reliably assess the BBB in physiologic and pathophysiologic states.</p>","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"121 ","pages":"1-88"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141154071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digital biomarkers in Parkinson's disease. 帕金森病的数字生物标记。
Advances in clinical chemistry Pub Date : 2024-01-01 Epub Date: 2024-06-22 DOI: 10.1016/bs.acc.2024.06.005
Anastasia Bougea
{"title":"Digital biomarkers in Parkinson's disease.","authors":"Anastasia Bougea","doi":"10.1016/bs.acc.2024.06.005","DOIUrl":"https://doi.org/10.1016/bs.acc.2024.06.005","url":null,"abstract":"<p><p>Digital biomarker (DB) assessments provide objective measures of daily life tasks and thus hold promise to improve diagnosis and monitoring of Parkinson's disease (PD) patients especially those with advanced stages. Data from DB studies can be used in advanced analytics such as Artificial Intelligence and Machine Learning to improve monitoring, treatment and outcomes. Although early development of inertial sensors as accelerometers and gyroscopes in smartphones provided encouraging results, the use of DB remains limited due to lack of standards, harmonization and consensus for analytical as well as clinical validation. Accordingly, a number of clinical trials have been developed to evaluate the performance of DB vs traditional assessment tools with the goal of monitoring disease progression, improving quality of life and outcomes. Herein, we update current evidence on the use of DB in PD and highlight potential benefits and limitations and provide suggestions for future research study.</p>","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"123 ","pages":"221-253"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142057797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glycosaminoglycans in mucopolysaccharidoses and other disorders. 粘多糖病和其他疾病中的糖胺聚糖。
Advances in clinical chemistry Pub Date : 2024-01-01 Epub Date: 2024-07-23 DOI: 10.1016/bs.acc.2024.06.011
Shaukat A Khan, Fnu Nidhi, Andrés Felipe Leal, Betul Celik, Angelica María Herreño-Pachón, Sampurna Saikia, Eliana Benincore-Flórez, Yasuhiko Ago, Shunji Tomatsu
{"title":"Glycosaminoglycans in mucopolysaccharidoses and other disorders.","authors":"Shaukat A Khan, Fnu Nidhi, Andrés Felipe Leal, Betul Celik, Angelica María Herreño-Pachón, Sampurna Saikia, Eliana Benincore-Flórez, Yasuhiko Ago, Shunji Tomatsu","doi":"10.1016/bs.acc.2024.06.011","DOIUrl":"10.1016/bs.acc.2024.06.011","url":null,"abstract":"<p><p>Glycosaminoglycans (GAGs) are sulfated polysaccharides comprising repeating disaccharides, uronic acid (or galactose) and hexosamines, including chondroitin sulfate, dermatan sulfate, heparan sulfate, and keratan sulfate. Hyaluronan is an exception in the GAG family because it is a non-sulfated polysaccharide. Lysosomal enzymes are crucial for the stepwise degradation of GAGs to provide a normal function of tissues and extracellular matrix (ECM). The deficiency of one or more lysosomal enzyme(s) results in the accumulation of undegraded GAGs, causing cell, tissue, and organ dysfunction. Accumulation of GAGs in various tissues and ECM results in secretion into the circulation and then excretion in urine. GAGs are biomarkers of certain metabolic disorders, such as mucopolysaccharidoses (MPS) and mucolipidoses. GAGs are also elevated in patients with various conditions such as respiratory and renal disorders, fatty acid metabolism disorders, viral infections, vomiting disorders, liver disorders, epilepsy, hypoglycemia, myopathy, developmental disorders, hyperCKemia, heart disease, acidosis, and encephalopathy. MPS are a group of inherited metabolic diseases caused by the deficiency of enzymes required to degrade GAGs in the lysosome. Eight types of MPS are categorized based on lack or defect in one of twelve specific lysosomal enzymes and are described as MPS I through MPS X (excluding MPS V and VIII). Clinical features vary with the type of MPS and clinical severity of the disease. This chapter addresses the historical overview, synthesis, degradation, distribution, biological role, and method for measurement of GAGs.</p>","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"122 ","pages":"1-52"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141904049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sputum proteomics in lung disorders. 肺部疾病中的痰蛋白质组学。
Advances in clinical chemistry Pub Date : 2024-01-01 Epub Date: 2024-06-18 DOI: 10.1016/bs.acc.2024.06.002
Paolo Iadarola, Maura D'Amato, Maria Antonietta Grignano, Simona Viglio
{"title":"Sputum proteomics in lung disorders.","authors":"Paolo Iadarola, Maura D'Amato, Maria Antonietta Grignano, Simona Viglio","doi":"10.1016/bs.acc.2024.06.002","DOIUrl":"https://doi.org/10.1016/bs.acc.2024.06.002","url":null,"abstract":"<p><p>Lung diseases affect pulmonary and respiratory function and are caused by bacterial viral and fungal infection as well as environmental factors. Unfortunately, symptom overlap between various pulmonary diseases often prevents clear differentiation and uncertain diagnosis. Accordingly, identification of specific markers of inflammatory activity in early disease stage could potential unveil the intrinsic molecular mechanisms of the underlying pathology. Proteomic studies aimed at understanding the genetic/environmental contributions to the development and progression of lung diseases represent a promising approach for diagnosis and treatment. The fluid phase of sputum represents a rich protein source and is frequently used in these studies. This chapter addresses causes of lung disorders, sputum composition, collection and processing as well as the clinical significance and challenges associated with the presence of interfering factors. Basics of proteomics and mass spectrometry are also described, together with the analytical approaches to investigate the sputum proteome. Finally, we explore the application of sputum proteomics in severe lung disorders including COVID-19 infection, chronic obstructive pulmonary disease, asthma, cystic fibrosis, lung cancer and tuberculosis.</p>","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"122 ","pages":"171-208"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141904116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Defining allowable total error limits in the clinical laboratory. 定义临床实验室允许的总误差限值。
Advances in clinical chemistry Pub Date : 2024-01-01 Epub Date: 2023-12-20 DOI: 10.1016/bs.acc.2023.11.006
Jill Palmer, Kornelia Galior
{"title":"Defining allowable total error limits in the clinical laboratory.","authors":"Jill Palmer, Kornelia Galior","doi":"10.1016/bs.acc.2023.11.006","DOIUrl":"https://doi.org/10.1016/bs.acc.2023.11.006","url":null,"abstract":"<p><p>Allowable total error (ATE) are performance specification limits predefined for a variety of laboratory analytes. These limits define the maximum amount of error that is allowed for an assay when judging acceptability of a new assay during method verification/validation, evaluating patient or instrument comparison data, or in designing a quality control strategy. There are several widely available resources and models that can serve as a guide in selecting ATE. They may be based on legal requirements or set by providers of proficiency testing (PT) and external quality assessment schemes (EQAS). ATE can be also determined by professional expert groups or be based on biological variation of an analyte. Because there are several resources to choose from, there have been several attempts in reaching consensus on which ATE resource should be given preference. This chapter reviews several of these resources in more detail and discusses the difference between allowable total error (ATE) and observed total analytical error (TAE).</p>","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"118 ","pages":"205-223"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139572161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autoantibody evaluation in idiopathic inflammatory myopathies. 特发性炎症性肌病的自身抗体评估。
Advances in clinical chemistry Pub Date : 2024-01-01 Epub Date: 2024-04-16 DOI: 10.1016/bs.acc.2024.04.001
Anne E Tebo
{"title":"Autoantibody evaluation in idiopathic inflammatory myopathies.","authors":"Anne E Tebo","doi":"10.1016/bs.acc.2024.04.001","DOIUrl":"https://doi.org/10.1016/bs.acc.2024.04.001","url":null,"abstract":"<p><p>Idiopathic inflammatory myopathies (IIM), generally referred to as myositis is a heterogeneous group of diseases characterized by muscle inflammation and/or skin involvement, diverse extramuscular manifestations with variable risk for malignancy and response to treatment. Contemporary clinico-serologic categorization identifies 5 main clinical groups which can be further stratified based on age, specific clinical manifestations and/or risk for cancer. The serological biomarkers for this classification are generally known as myositis-specific (MSAs) and myositis-associated antibodies. Based on the use of these antibodies, IIM patients are classified into anti-synthetase syndrome, dermatomyositis, immune-mediated necrotizing myopathy, inclusion body myositis, and overlap myositis. The current classification criteria for IIM requires clinical findings, laboratory measurements, and histological findings of the muscles. However, the use MSAs and myositis-associated autoantibodies as an adjunct for disease evaluation is thought to provide a cost-effective personalized approach that may not only guide diagnosis but aid in stratification and/or prognosis of patients. This review provides a comprehensive overview of contemporary autoantibodies that are specific or associated myositis. In addition, it highlights possible pathways for the detection and interpretation of these antibodies with limitations for routine clinical use.</p>","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"120 ","pages":"45-67"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140961434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信